Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc. was incorporated in 2015 and is based in Bedford, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: homologymedicines.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/28/2023 | $9.00 → $1.50 | Outperform → Neutral | Robert W. Baird |
| 2/28/2022 | $30.00 → $20.00 | Buy | HC Wainwright & Co. |
| 2/22/2022 | $25.00 → $9.00 | Buy | B of A Securities |
| 2/22/2022 | $35.00 → $29.00 | Neutral | BTIG Research |
| 2/22/2022 | Outperform → Sector Perform | RBC Capital Mkts | |
| 2/22/2022 | $25.00 → $15.00 | Buy | Chardan Capital |
| 2/22/2022 | $35.00 → $29.00 | Buy | BTIG |
| 2/22/2022 | $30.00 → $4.00 | Outperform → Sector Perform | RBC Capital |
| 2/22/2022 | Outperform → Perform | Oppenheimer | |
| 11/16/2021 | $30.00 → $25.00 | Buy | Chardan Capital |
424B3 - Q32 Bio Inc. (0001661998) (Filer)
10-Q - Q32 Bio Inc. (0001661998) (Filer)
8-K - Q32 Bio Inc. (0001661998) (Filer)
EFFECT - Q32 Bio Inc. (0001661998) (Filer)
424B3 - Q32 Bio Inc. (0001661998) (Filer)
S-1 - Q32 Bio Inc. (0001661998) (Filer)
10-K/A - Q32 Bio Inc. (0001661998) (Filer)
8-K - Q32 Bio Inc. (0001661998) (Filer)
8-K/A - Homology Medicines, Inc. (0001661998) (Filer)
8-K - Homology Medicines, Inc. (0001661998) (Filer)
Robert W. Baird downgraded Homology Medicines from Outperform to Neutral and set a new price target of $1.50 from $9.00 previously
HC Wainwright & Co. reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $20.00 from $30.00 previously
B of A Securities reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $9.00 from $25.00 previously
BTIG Research reiterated coverage of Homology Medicines with a rating of Neutral and set a new price target of $29.00 from $35.00 previously
RBC Capital Mkts downgraded Homology Medicines from Outperform to Sector Perform
Chardan Capital reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $15.00 from $25.00 previously
BTIG reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $29.00 from $35.00 previously
RBC Capital downgraded Homology Medicines from Outperform to Sector Perform and set a new price target of $4.00 from $30.00 previously
Oppenheimer downgraded Homology Medicines from Outperform to Perform
Chardan Capital reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $25.00 from $30.00 previously